Enimmune Corporation (TPEX:6564)
Taiwan · Delayed Price · Currency is TWD 16.50
+0.40 (2.48%)
Aug 26, 2026, 1:47 PM CST
Enimmune Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 53.45 | 48.19 | 39.92 | 43.49 | 188.42 | 109.82 | |
Revenue Growth | 26.56% | 20.74% | -8.23% | -76.92% | 71.56% | 380.07% |
Cost of Revenue | 49.14 | 40.18 | 25.69 | 66.87 | 167.57 | 71.1 |
Gross Profit | 4.31 | 8.02 | 14.23 | -23.37 | 20.84 | 38.72 |
Selling, General & Admin | 68.63 | 77.71 | 80.57 | 80.66 | 54.96 | 42.57 |
Research & Development | 59.95 | 117.13 | 84.95 | 139.27 | 247.38 | 54.76 |
Operating Expenses | 128.57 | 193.26 | 165.37 | 220.1 | 307.26 | 97.39 |
Operating Income | -124.27 | -185.24 | -151.14 | -243.48 | -286.42 | -58.67 |
Interest Expense | -4.49 | -4.01 | -2.2 | -0.98 | -0.32 | -0.23 |
Interest & Investment Income | 3.92 | 3.58 | 2.58 | 1.94 | 1.29 | 2.39 |
Currency Exchange Gain (Loss) | 0.21 | 0.1 | -0.6 | -0.34 | 7.45 | 0.01 |
Other Non Operating Income (Expenses) | 3.75 | 21.04 | -14.21 | 5.16 | 10.9 | 9.25 |
Pretax Income | -120.88 | -164.54 | -165.57 | -237.69 | -267.09 | -47.25 |
Earnings From Continuing Operations | -120.88 | -164.54 | -165.57 | -237.69 | -267.09 | -47.25 |
Minority Interest in Earnings | - | 0.19 | 8.03 | 13.95 | 19.12 | - |
Net Income | -120.88 | -164.35 | -157.55 | -223.74 | -247.96 | -47.25 |
Net Income to Common | -120.88 | -164.35 | -157.55 | -223.74 | -247.96 | -47.25 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 72 | 72 | 72 | 66 | 64 | 60 |
Shares Outstanding (Diluted) | 72 | 72 | 72 | 66 | 64 | 60 |
Shares Change | -2.64% | 0.86% | 8.70% | 3.03% | 6.44% | 12.50% |
EPS (Basic) | -1.68 | -2.28 | -2.20 | -3.40 | -3.88 | -0.79 |
EPS (Diluted) | -1.68 | -2.28 | -2.20 | -3.40 | -3.88 | -0.79 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -86.19 | -147.43 | -144.25 | -138.13 | -200.98 | -74.53 |
Free Cash Flow Per Share | -1.20 | -2.04 | -2.02 | -2.10 | -3.15 | -1.24 |
Gross Margin | 8.06% | 16.63% | 35.64% | -53.74% | 11.06% | 35.26% |
Operating Margin | -232.49% | -384.36% | -378.66% | -559.79% | -152.01% | -53.42% |
Profit Margin | -226.16% | -341.01% | -394.70% | -514.42% | -131.60% | -43.02% |
Free Cash Flow Margin | -161.26% | -305.91% | -361.39% | -317.59% | -106.67% | -67.86% |
EBITDA | -117.77 | -179.22 | -145.53 | -237.71 | -280.06 | -50.19 |
EBITDA Margin | -220.33% | - | - | - | -148.64% | -45.70% |
D&A For EBITDA | 6.5 | 6.02 | 5.61 | 5.77 | 6.35 | 8.49 |
EBIT | -124.27 | -185.24 | -151.14 | -243.48 | -286.42 | -58.67 |
EBIT Margin | -232.49% | - | - | - | -152.01% | -53.42% |